Clinical Trials Logo

Pharmacokinetic clinical trials

View clinical trials related to Pharmacokinetic.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06378125 Recruiting - Safety Issues Clinical Trials

Evaluation of Safety and Pharmacokinetics of Oral Controlled-ileal-release Nicotinic Acid (CIR-NA) Compared to Immediate-release Nicotinic Acid and Placebo in Healthy Subjects and Subjects With Prediabetes

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

A double-blind, randomised, placebo-controlled, single-ascending and multiple-ascending dose trial to evaluate the safety and pharmacokinetics of oral controlled-ileal-release nicotinic acid (CIR-NA) compared to immediate-release nicotinic acid and placebo in healthy subjects and subjects with prediabetes.

NCT ID: NCT06344858 Recruiting - Analgesia Clinical Trials

Characterization of the Temporal Profile of the Anti-nociceptive Effect of Ketamine Bolus Measured With ANI

Keta-ANI
Start date: April 30, 2024
Phase:
Study type: Observational [Patient Registry]

Ketamine, an intravenous anesthetic, and analgesic agent has experienced a resurgence in its clinical application, particularly in subanesthetic doses. The aim of this observational study is to characterize the changes in the Nociception Analgesia Index (ANI) associated with the administration of an intravenous ketamine bolus using a Pharmacokinetic-Pharmacodynamic (PKPD) modeling approach. The pharmacokinetic parameters of the Domino model will be used to predict ketamine plasma concentrations after the bolus dose. An Emax model and a link model assuming a first order rate constant (ke0) will be used to fit the data. Modeling analysis will use the program NONMEM. It is expected to recruit a total of 20 patients between 40 and 80 years, ASA I, II or III, programmed for elective surgery with general anesthesia. ANI values will be recorded every 6 seconds for 5 minutes from the bolus dose.

NCT ID: NCT04080895 Recruiting - Healthy Clinical Trials

Pharmacokinetic Study of Artemether-lumefantrine and Amodiaquine in Healthy Subjects

ALAQ
Start date: November 1, 2022
Phase: Phase 1
Study type: Interventional

This is an open-label pharmacokinetic study in 16 healthy Thai subjects. To assess the safety and tolerability and pharmacological interactions of the combination of artemether-lumefantrine and amodiaquine. This study is funded by Prof White's WT PRF. The Welcome Trust grant reference number is B9R04920.

NCT ID: NCT03714568 Recruiting - Pharmacokinetic Clinical Trials

Pharmacokinetic and Tolerance Study of TQ-A3326 in Healthy Participants.

Start date: November 11, 2018
Phase: Phase 1
Study type: Interventional

To study the single dose and multi-doses pharmacokinetic characteristics and tolerance of TQ-A3326 in the human body;To study the transformation of TQ-A3326;To study the effect of the food on the pharmacokinetic characteristics of TQ-A3326.